Clinical monitoring of patients with age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab

Ophthalmic Surgery Lasers and Imaging Retina

Volumn 45, Issue 4, 2014, Pages 285-291

  Kiss, Szilárd ^a   Liu, Ying ^b   Brown, Joseph ^c   Holekamp, Nancy M ^d   Almony, Arghavan ^e   Campbell, Joanna ^b   Kowalski, Jonathan W ^b  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b ALLERGAN INC   (United States)

^c IQVIA   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Carolina Eye Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

AGED; ARTICLE; CLINICAL PRACTICE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPHTHALMOLOGIST; OPTICAL COHERENCE TOMOGRAPHY; PATIENT MONITORING; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; ANALYSIS OF VARIANCE; DRUG ADMINISTRATION; INTRAVITREAL DRUG ADMINISTRATION; MACULAR DEGENERATION; RETROSPECTIVE STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; RETROSPECTIVE STUDIES;

EID: 84925548874     PISSN: 23258160     EISSN: 23258179     Source Type: Journal    
DOI: 10.3928/23258160-20140709-04     Document Type: Article

References (32)

1. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA. 2004;291(15):1900-1901.
2. Congdon N, O'Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122(4):477-485.
3. Muñoz B, West SK, Rubin GS, et al. Causes of blindness and visual impairment in a population of older Americans: The Salisbury Eye Evaluation Study. Arch Ophthalmol. 2000;118(6):819-825.
4. Lally DR, Gerstenblith AT, Regillo CD. Preferred therapies for neovascular age-related macular degeneration. Curr Opin Ophthalmol. 2012;23:182-188.
5. You JY, Chung H, Kim HC. Evaluation of changes in choroidal neovascularization secondary to age-related macular degeneration after anti-VEGF therapy using spectral domain optical coherence tomography. Curr Eye Res. 2012;37(5):438-445.
6. Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess. 2008;12(16): iii-iv, ix-201.
7. Takeda AL, Colquitt J, Clegg AJ, Jones J. Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review. Br J Ophthalmol. 2007;91(9):1177-1182.
8. Vedula SS, Krzystolik MG. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2008;16(2): CD005139.
9. Chakravarthy U, Harding S P, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119:1399-1411.
10. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin D F, Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388-1398.
11. CATT Research Group, Martin D F, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897-1908.
12. Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology. 2009;116:1731-1739.
13. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-1444.
14. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143(4):566-583.
15. Regillo CD, Brown DM, Abraham P, et al. Randomized, doublemasked, sham-controlled trial of ranibizumab for neovascular agerelated macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145(2):239-248.
16. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431.
17. Schmidt-Erfurth U, Eldem B, Guymer R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology. 2011;118(5):831-839.
18. Fong DS, Custis P, Howes J, Hsu JW. Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study. Ophthalmology. 2010;117(2):298-302.
19. Holekamp NM, Yeh W.-S., Chia Y, et al. Real-world utilization of intravitreal anti-vascular endothelial growth factor agents in common retinal diseases. Invest Ophthalmol Vis Sci. 2012;53:4179.
20. Chakravarthy U, Harding S P, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013;382(9900):1258-1267.
21. Busbee BG, Ho AC, Brown DM, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120(5):1046-1056.
22. Bandello F, Holz FG, Gillies MC, et al. Safety, efficacy, and treatment patterns of ranibizumab therapy for neovascular age-related macular degeneration: the LUMINOUS studies. Invest Ophthalmol Vis Sci. 2012;53:2031.
23. Bandukwala T, Muni RH, Schwartz C, Eng KT, Kertes PJ. Effectiveness of intravitreal ranibizumab for the treatment of neovascular agerelated macular degeneration in a Canadian retina practice: a retrospective review. Can J Ophthalmol. 2010;45(6):590-595.
24. Cohen SY, Mimoun G, Oubraham H, et al. Changes in visual acuity in patients with wet age-related macular degernation treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study. Retina. 2013;33(3):474-481.
25. Rotsos T, Patel PJ, Chen FK, Tufail A. Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration. Clin Ophthalmol. 2010;4:1271-1275.
26. Cohen SY, Dubois L, Tadayoni R, et al. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Am J Ophthalmol. 2009;148(3):409-413.
27. American Society of Retinal Specialists (ASRS). Annual Preferences and Trends Survey. 2012; http://www.asrs.org: access for members only.
28. Cleary CA, Sharaznayan D, Hickey-Dwyer M. Intravitreal anti-VEGF therapy for neovascular age-related macular degeneration and the risk of stroke. Ir Med J. 2011;104(5):146-149.
29. Costagliola C, Agnifili L, Arcidiacono B, et al. Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration. Expert Opin Biol Ther. 2012;12(10):1299-1313.
30. Eghøj MS, Sørensen TL. Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol. 2012;96(1):21-23.
31. Mitchell P. A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab. Curr Med Res Opin. 2011;27(7):1465-1475.
32. Singer MA, Awh CC, Sadda S, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012;119(6):1175-1183.